Adjuvant chemotherapy for non-small cell lung cancer

Semin Thorac Cardiovasc Surg. 2005 Fall;17(3):195-8. doi: 10.1053/j.semtcvs.2005.06.010.

Abstract

The survival after complete resection for non-small cell lung cancer (NSCLC) is unsatisfactory. Until recently, the use of adjuvant therapy after resection for early stage disease has not been proven to improve survival. However, the efficacy of adjuvant therapy has been demonstrated in phase III prospective randomized trials. The appropriate use of adjuvant therapy, including biologic therapy, is currently under investigation.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / surgery*
  • Chemotherapy, Adjuvant
  • Erlotinib Hydrochloride
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / mortality
  • Lung Neoplasms / surgery*
  • Oncogene Proteins
  • Protein Kinase Inhibitors / therapeutic use
  • Quinazolines / therapeutic use

Substances

  • Antineoplastic Agents
  • Oncogene Proteins
  • Protein Kinase Inhibitors
  • Quinazolines
  • survival-related gene product, human
  • Erlotinib Hydrochloride
  • Gefitinib